Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial

Diabetes, Obesity and Metabolism

Volumn 18, Issue 2, 2016, Pages 186-190

  Leiter, L A ^a   Teoh, H ^a,b   Mosenzon, O ^c   Cahn, A ^c   Hirshberg, B ^d   Stahre, C A M ^e   Hoekstra, J B L ^f   Alvarsson, M ^g   Im, K ^h   Scirica, B M ^h   Bhatt, D L ^h   Raz, I ^c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d ASTRAZENECA   (United Kingdom)

^e ASTRAZENECA R AND D   (Sweden)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

^g KAROLINSKA INSTITUTE   (Sweden)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antihyperglycemic agents; Cancer; Saxagliptin

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; PLACEBO; SAXAGLIPTIN; ADAMANTANE; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ADULT; AGE; AGED; CANCER INCIDENCE; CANCER MORTALITY; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG SAFETY; DRUG USE; DYSLIPIDEMIA; ETHNICITY; FEMALE; FOLLOW UP; GENDER; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY (TOPIC); SMOKING; TREATMENT DURATION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; GLOMERULUS FILTRATION RATE; KIDNEY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASMS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX DIFFERENCE;

ADAMANTANE; AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; MIDDLE AGED; MORTALITY; NEOPLASMS; RISK FACTORS; SEX FACTORS; SMOKING;

EID: 84956927873     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12582     Document Type: Letter

References (16)

1. Bordeleau L, Yakubovich N, Dagenais GR etal. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care 2014; 37: 1360-1366.
2. Cahn A, Raz I. Emerging gliptins for type 2 diabetes. Expert Opin Emerg Drugs 2013; 18: 245-258.
3. Connelly KA, Yan AT, Leiter LA, Bhatt DL, Verma S. Cardiovascular implications of hypoglycemia in diabetes. Circulation (in press).
4. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013; 62: 2595-2604.
5. Scirica BM, Bhatt DL, Braunwald E etal. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
6. Raz I, Bhatt DL, Hirshberg B etal. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin. Diabetes Care 2014; 37: 2435-2441.
7. Harding JL, Shaw JE, Peeters A, Cartensen B, Magliano DJ. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. Diabetes Care 2015; 38: 264-270.
8. Handelsman Y, Leroith D, Bloomgarden ZT etal. Diabetes and cancer-an AACE/ACE consensus statement. Endocr Pract 2013; 19: 675-693.
9. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-1777.
10. Col NF, Ochs L, Springmann V, Aragaki AK, Chlebowski RT. Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat 2012; 135: 639-646.
11. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012; 35: 299-304.
12. Bosetti C, Rosato V, Buniato D, Zambon A, La Vecchia C, Corrao G. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist 2013; 18: 148-156.
13. U.S. Food and Drug Administration. Background document: dapagliflozin (BMS-512148, NDA 202293). 2013. Available from URL: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm378079.pdf. Accessed 29 July, 2015.
14. Yao X, Tian Z. Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies. Cancer Causes Control 2015; 26: 257-268.
15. Udell JA, Bhatt DL, Braunwald E etal. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 2015; 38: 696-705.
16. Leiter LA, Teoh H, Braunwald E etal. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care 2015; 38: 1145-1153.